Abstract | OBJECTIVE: METHODS: RESULTS: In study 1, there was a significantly greater relative risk (RR) for bleeding in the group receiving 1 mg norethindrone acetate/10 microg ethinyl E2 at study weeks 4 and 8 (RR = 1.36 and 95% confidence interval [CI] 1.01, 1.83; RR = 1.37 and 95% CI 1.1, 1.72; respectively) compared with placebo, but not at study weeks 12 or 16. The group receiving 1 mg norethindrone acetate/5 microg ethinyl E2 also had a significantly greater risk at weeks 4 and 8 (RR = 1.5 and 95% CI 1.15, 1.96; RR = 1.33 and 95% CI 1.00, 1.77; respectively), whereas the other dose combinations did not differ from placebo. Results from study 2 were similar to those of study 1. CONCLUSION:
|
Authors | J Symons, N Kempfert, L Speroff |
Journal | Obstetrics and gynecology
(Obstet Gynecol)
Vol. 96
Issue 3
Pg. 366-72
(Sep 2000)
ISSN: 0029-7844 [Print] United States |
PMID | 10960627
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Ethinyl Estradiol
- Norethindrone Acetate
- Norethindrone
|
Topics |
- Adult
- Aged
- Climacteric
(drug effects)
- Dose-Response Relationship, Drug
- Drug Therapy, Combination
- Estrogen Replacement Therapy
- Ethinyl Estradiol
(administration & dosage, adverse effects)
- Female
- Humans
- Middle Aged
- Norethindrone
(administration & dosage, adverse effects, analogs & derivatives)
- Norethindrone Acetate
- Risk
- Uterine Hemorrhage
(chemically induced)
|